Head and neck squamous cell carcinoma cell lines are highly sensitive to the new taxanes, BMS-184476, BMS-188797, in vitro

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 3769-3773

  Raitanen, Misa ^a   Pulkkinen, Jaakko ^a   Kulmala, Jarmo ^a   Grénman, Reidar ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemosensitivity; Clonogenic assay; Head and neck squamous cell carcinoma; Paclitaxel; Taxane analogues

Indexed keywords

BMS 184476; BMS 188797; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; 7 METHYLTHIOMETHYLPACLITAXEL; 7-METHYLTHIOMETHYLPACLITAXEL; BMS188797; TAXOID;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LARYNX CARCINOMA; MICROSCOPY; MITOSIS INHIBITION; MOUTH CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; DRUG SCREENING; HEAD AND NECK TUMOR; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HEAD AND NECK NEOPLASMS; HUMANS; MICROSCOPY, VIDEO; PACLITAXEL; TAXOIDS;

EID: 14944352401     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Forastiere AA: Head and neck cancer: overview of recent developments and future directions. Semin Oncol 27: 1-4, 2000.
2. Forastiere A, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-8, 2003.
3. Suntharalingam M: The role of concurrent chemotherapy and radiation in the management of patients with squamous cell carcinomas of the head and neck. Semin Oncol 30: 37-45, 2003.
4. Rowinsky EK: The taxanes: dosing and scheduling considerations. Oncology (Huntingt) 11(3 Suppl 2): 7-19, 1997.
5. Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC and Adams GL: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 15: 1088-95, 2001.
6. Ghersi D, Wilcken N, Simes J and Donoghue E: Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (3): CD003366, 2003.
7. Herzog TJ, Holloway RW and Stuart GC: Workshop: options for therapy in ovarian cancer. Gynecol Oncol 90(3 Pt 2): S45-50, 2003.
8. Solomon B, Ball DL, Richardson G, Smith JG, Millward M, MacManus M, Michael M, Wirth A, O'Kane C, Muceniekas L, Ryan G and Rischin D: Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer 41(3): 353-61, 2003.
9. Rose WC, Fairchild C and Lee FY: Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol 47: 97-105, 2001.
10. Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J Jr, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E et al: Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 19: 2493-503, 2001.
11. Ferrante K, Winograd B and Canetta R: Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 43: 61-8, 1999.
12. Felip E: New anti-tubulin agents. Suppl Tumori 1: 17-8, 2002.
13. Bergh J, Lidbrink M, Albertsson M, Aloe A, Voi M, Dank M, Jacobsen E, Kocak E, Lang I, Lokkevik E, Padrik P, Pienkowski T et al: A randomized phase II study of two different schedules of BMS-184476-a novel taxane, in patients with previously anthracycline treated metastatic breast cancer. Proceedings of ASCO 53a, 2002.
14. Poole CJ, Thomas H, Jayson G, Higgins H, Bomphray C, Clamp A, Hewitt P, Siakpere P, Aloe A, Astier L, Kaye SB and Gore M: Phase II clinical trial of BMS-184476, a novel taxane, administered at days 1 and 8 every 28 days in patients (pts) with relapsed epithelial ovarian cancer (EOC) previously treated with platinum and paclitaxel-based chemotherapy. Proceedings of ASCO 209a, 2002.
15. Advani R, Fisher R, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A and Sikic BI: Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res 9: 5187-94, 2003.
16. Grénman R, Carey TE, McClatchey KD, Wagner JG, Pekkola-Heino K, Schwartz DR, Wolf GT, Lacivita LP, Ho L, Baker SR, Krause CJ and Lichter AS: In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer 67: 2741-7, 1991.
17. Erjala K, Pulkkinen J, Kulmala J, Alanen K and Grenman R: Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vitro. Anticancer Res 22(6A): 3135-42, 2002.
18. Grénman R, Burk D, Virolainen E, Wagner JG, Lichter AS and Carey TE: Clonogenic cell assay for anchorage-dependent squamous cell carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-6, 1989.
19. Pulkkinen JO, Elomaa L, Joensuu H, Martikainen P, Servomaa K and Grénman R: Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 122: 214-8, 1996.
20. Akerley W and Choy H: Single-agent paclitaxel and radiation for non-small cell lung cancer. Semin Radiat Oncol 2: 85-9, 1999.
21. Rosenthal DI, Lee JH, Sinard R, Yardley DA, Machtay M, Rosen DM, Egorin MJ, Weber RS, Weinstein GS, Chalian AA, Miller LK, Frenkel EP et al: Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 19: 1363-73, 2001.
22. Weiss RB, Donehower RC, Wiernic PH, Ohnumma T, Gralla RJ, Trump DL, Baker RJ, Van Echo DA, Von Hoff DD and Leyland-Jones B: Hypersensitivity reactions from Taxol. J Clin Oncol 8: 1263-8, 1990.
23. Altstadt TJ, Fairchild CR, Golik J, Johnston KA, Kadow JF, Lee FY, Long BH, Rose WC, Vyas DM, Wong H, Wu MJ and Wittman MD: Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476. J Med Chem 44: 4577-83, 2001.
24. Plummer R, Ghielmini M, Calvert P, Voi M, Renard J, Gallant G, Gupta E, Calvert H and Sessa C: Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin Cancer Res 8: 2788-97, 2002.
25. Engblom P, Rantanen V, Kulmala J, Heiskanen J and Grénman S: Taxane sensitivity of ovarian carcinoma in vitro. Anticancer Res 17: 2475-2480, 1997.
26. Jaakkola M, Rantanen V, Grénman S, Kulmala J and Grénman R: Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro. Anticancer Res 17: 939-44, 1997.
27. Kim JS, Amorino GP, Pyo H, Cao Q, Price JO and Choy H: The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys 51: 525-34, 2001.